Melinta Medical Affairs

Publications

Read published literature about our products or browse articles about antimicrobial resistance and associated disease states.

Click on a product below to browse recent publications related to Melinta products and associated disease states
 

 

REZZAYO

Review Articles

Rezafungin: First Approval.
Drugs. 2023;83(9):833-840.

VABOMERE

KIMYRSA and ORBACTIV

In Vitro Microbiology and Pharmacology Studies

Population Pharmacokinetic Analysis for a Single 1,200-milligram Dose of Oritavancin using data from Two Pivotal Phase 3 Clinical Trials.
Antimicrob Agents Chemother. 2015;59(6):3365-72.

BAXDELA

Registrational and Pivotal Trial Data

A Phase 3 Study to Compare Delafloxacin with Moxifloxacin for the Treatment of Adults with Community-Acquired Bacterial Pneumonia (DEFINE-CABP).
Open Forum Infect Dis. 2019;7(1):ofz514..

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
Antimicrob Agents Chemother. 2020;97:374-379..

A Randomized, Double-Blind, Phase 2 Study to Evaluate Subjective and Objective Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections Treated with Delafloxacin, Linezolid or Vancomycin.
J Antimicrob Chemother. 2016;71(3):821-9..

Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Clin Infect Dis. 2019;68(Suppl 3):S233-S240.  .

Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Clin Infect Dis. 2019;68(Suppl 3):S223-S232..

Efficacy of Delafloxacin Versus Moxifloxacin against Atypical Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
Int J Infect Dis. 2020;97:374-379.  .

A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
Clin Infect Dis. 2018;67(5):657-666.  .

External links on this page are not affiliated with Melinta Therapeutics. Links to sites outside of Melinta are provided as a resource to the viewer. Melinta accepts no responsibility for the content of linked sites. The publications above are intended to share pertinent data regarding Melinta products and associated disease states. The views expressed by the authors are their own, and do not necessarily represent those of Melinta.

Email

medinfo@melinta.com
or click here to access
our online form.
“AE”

Report an Adverse Event or Quality Complaint

Call 1-844-MED-MLNT
(+1 844-633-6568).
You may also report suspected
adverse events to the FDA
at 1-800-FDA-1088 or
https://www.fda.gov/medwatch
“QR”

Scan

Access Melinta Medical
Information Library

NEWR Call

1-844-med-mlnt
(+1 844-633-6568)
to speak with a medical
information representative
“AE”

Report an Adverse Event
or Quality Complaint

Call 1-844-MED-MLNT
(+1 844-633-6568)
.
You may also report suspected
adverse events to the FDA
at 1-800-FDA-1088 or
https://www.fda.gov/medwatch
“QR”

CallB

1-844-MED-MLNT
(+1 844-633-6568)
to speak with a Medical
Information Representative